Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Fennec Pharmaceuticals Inc (FENC)

Fennec Pharmaceuticals Inc (FENC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 190,602
  • Shares Outstanding, K 26,003
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,780 K
  • 60-Month Beta 0.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.06
Trade FENC with:

Options Overview

Details
  • Implied Volatility 43.51%
  • Historical Volatility 51.08%
  • IV Percentile 1%
  • IV Rank 7.18%
  • IV High 409.71% on 03/20/20
  • IV Low 15.19% on 03/02/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 66

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.19
  • Number of Estimates 1
  • High Estimate -0.19
  • Low Estimate -0.19
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -5.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.10 +7.88%
on 03/01/21
8.84 -13.35%
on 02/10/21
-0.15 (-1.92%)
since 02/03/21
3-Month
6.52 +17.48%
on 12/24/20
8.84 -13.35%
on 02/10/21
-0.19 (-2.42%)
since 12/03/20
52-Week
4.65 +64.73%
on 03/18/20
10.67 -28.21%
on 08/10/20
+0.69 (+9.90%)
since 03/03/20

Most Recent Stories

More News
New Strong Sell Stocks for December 9th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

NBIX : 95.01 (-6.32%)
NBEV : 2.81 (-3.44%)
FENC : 7.66 (+4.50%)
SLDB : 9.89 (-7.74%)
GHG : 13.20 (-2.87%)
New Strong Sell Stocks for November 27th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

ESLT : 132.04 (-1.46%)
CRTX : 35.19 (-3.35%)
AVD : 20.44 (+1.44%)
NEWR : 59.35 (-4.18%)
FENC : 7.66 (+4.50%)
New Strong Sell Stocks for November 19th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

CLSN : 2.04 (-4.67%)
EMAN : 4.74 (-2.07%)
MCY : 60.67 (+1.10%)
FENC : 7.66 (+4.50%)
ALRN : 1.4500 (-5.84%)
Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), ("Processa" or the "Company"), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients...

PCSA : 12.04 (-6.16%)
FENC : 7.66 (+4.50%)
IMMU : 87.86 (+0.05%)
FENC Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and Lead Plaintiff Deadline: November 2, 2020

New York, New York--(Newsfile Corp. - November 2, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec"...

FENCF : 7.0048 (unch)
FENC : 7.66 (+4.50%)
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 2, 2020) -  , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceuticals Inc. ("Fennec"...

FENCF : 7.0048 (unch)
FENC : 7.66 (+4.50%)
FENC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 2, 2020 in the Class Action Filed on Behalf of Fennec Pharmaceuticals Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - November 2, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fennec Pharmaceuticals Inc. (NASDAQ: FENC)...

FENCF : 7.0048 (unch)
FENC : 7.66 (+4.50%)
LAWSUITS FILED AGAINST POR, FENC and CLNC - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / November 2, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who...

POR : 42.05 (+1.50%)
FENC : 7.66 (+4.50%)
CLNC : 8.84 (+3.27%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Fennec Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 2, 2020 - FENC

New York, New York--(Newsfile Corp. - November 2, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

FENCF : 7.0048 (unch)
FENC : 7.66 (+4.50%)
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of POR, FENC and NKLA

NEW YORK, NY / ACCESSWIRE / November 2, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies....

POR : 42.05 (+1.50%)
FENC : 7.66 (+4.50%)
NKLA : 16.54 (-7.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 8.57
2nd Resistance Point 8.21
1st Resistance Point 7.93
Last Price 7.66
1st Support Level 7.29
2nd Support Level 6.93
3rd Support Level 6.65

See More

52-Week High 10.67
Fibonacci 61.8% 8.37
Fibonacci 50% 7.66
Last Price 7.66
Fibonacci 38.2% 6.95
52-Week Low 4.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar